| Nov 22 |
Xencor: Plamotamab NHL Data Leads To RA Program Advancement
|
| Nov 18 |
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade
|
| Nov 14 |
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
|
| Nov 12 |
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%
|
| Nov 7 |
Xencor GAAP EPS of -$0.71 beats by $0.30, revenue of $10.71M misses by $2.62M
|
| Nov 6 |
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 6 |
Xencor: Q3 Earnings Snapshot
|
| Nov 6 |
Xencor Reports Third Quarter 2024 Financial Results
|
| Nov 4 |
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
|
| Nov 1 |
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?
|
